Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer

Brian Y. ParkDepartment of Internal Medicine, Loma Linda University Medical Center, Loma Linda, California, USACorrespondence[email protected]

Rachel N. GrishamDepartment of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

Bjørnar den HollanderDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Dharmarao ThapiDepartment of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

Tara BermanDepartment of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Qin ZhouDepartment of Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Gopa IyerDepartment of Medicine, GU Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

Carol AghajanianDepartment of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

David R. SpriggsDepartment of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA

show all

References

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371: 424–433.
PubMed Web of Science ®Google Scholar
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014;16:R7.
PubMed Web of Science ®Google Scholar
Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, et al. Pre-clinical evaluation of the AR inhibitor enzalutamide in triple negative breast cancer cells. Endocr Relat Cancer 2016;23:323–334.
PubMed Web of Science ®Google Scholar
Evangelou A, Jindal SK, Brown TJ, Letarte M. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000;60:929–935.
PubMed Web of Science ®Google Scholar
Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res 2014;20:5150–5156.
PubMed Web of Science ®Google Scholar
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. National Cancer Institute, SEER Cancer Statistics Review, 1975–2013, Based on November 2015 SEER Data Submission. Bethesda, MD: National Cancer Institute; 2016.
Google Scholar
Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 1987;26:393–397.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date